Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.61%
#2 Luxxcoin Luxxcoin +45.15%
#3 ResearchCoin ResearchCoin +21.62%
#4 Reactive Network Reactive Network +21.45%
#5 Layer3 Layer3 +19.67%
#6 Orderly Network Orderly Network +16.55%
#7 Aria.AI Aria.AI +12.61%
#8 Bitgert Bitgert +11.76%
#9 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +9.32%
#10 KAITO KAITO +9.04%
Coin of the day
Resolv wstUSR Resolv wstUSR
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
CSL Limited CSL Limited

CSL Limited

CSL
Kedudukan dalam Saham #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Harga Saham
$99.32
Modal Pasaran
$48.20B
Perubahan (1 hari)
0.98%
Perubahan (1 tahun)
-32.14%
Negara
AU
Perdagangan CSL Limited (CSL)

Kategori

Healthcare
Pendapatan untuk CSL Limited (CSL)
Pendapatan pada Dec 2025 TTM: $1.61B
Menurut laporan kewangan terkini CSL Limited, pendapatan semasa syarikat ialah $1.61B. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $3.38B, peningkatan berbanding pendapatan pada tahun 2023 yang berjumlah $2.66B. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi CSL Limited dari 2000 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $1.61B -56.65%
2025 $3.72B 10.34%
2024 $3.38B 26.74%
2023 $2.66B -4.19%
2022 $2.78B -6.80%
2021 $2.98B 15.92%
2020 $2.57B 9.89%
2019 $2.34B 2.63%
2018 $2.28B 35.00%
2017 $1.69B 8.61%
2016 $1.56B -9.22%
2015 $1.71B 6.84%
2014 $1.60B 19.64%
2013 $1.34B 5.36%
2012 $1.27B -7.31%
2011 $1.37B 38.29%
2010 $992.87M 11.00%
2009 $894.45M 2.37%
2008 $873.74M 56.73%
2007 $557.47M 493.43%
2006 $93.94M -74.77%
2005 $372.39M 201.20%
2004 $123.64M 168.99%
2003 $45.96M -7.38%
2002 $49.63M -8.38%
2001 $54.17M 88.04%
2000 $28.81M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.51B 1,170.24%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B 187.63%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B 224.03%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B 32.42%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -10.11%
NL